Results 271 to 280 of about 360,596 (308)

Dermatitis herpetiformis

Springer Seminars in Immunopathology, 1981
R P, Hall, T J, Lawley, S I, Katz
openaire   +2 more sources

Solar Dermatitis

Archives of Dermatology, 1950
J H, LAMB, B, SHELMIRE, Z, COOPER, R J, MORGAN, C, KEATY   +4 more
openaire   +3 more sources

Dermatitis

The Journal of the American Dental Association, 1979
openaire   +2 more sources

Dermatitis

Primary Care: Clinics in Office Practice, 1983
openaire   +2 more sources

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Lancet, The, 2022
Kilian Eyerich, Fernando Valenzuela
exaly  

[Common dermatitis in infants (dermatitis seborrheica, atopic dermatitis and "diaper dermatitis")].

Pediatrie (Bucharest, Romania), 1993
The most common dermatoses during early infancy are: seborrheic dermatitis, atopic dermatitis and diaper dermatitis. It is important to differentiate these conditions for prognostic and therapeutic reasons.
openaire   +1 more source

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
Michael J Cork, Andreas Wollenberg, Mercedes E. Gonzalez   +2 more
exaly  

Perioral Dermatitis

Dermatology, 1970
E, van Dijk, G L, Kalsbeek, , Verburgh-van der Zwan   +2 more
openaire   +3 more sources

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
Kristian Reich, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Lancet, The, 2023
E Guttman-Yassky, Kenji Kabashima, Masutaka Furue   +2 more
exaly